Oak Ridge National Laboratory (ORNL) is advancing the development of medical radioisotopes crucial for cancer treatments. The facility houses over 300 isotopes, including actinium-225 and lead-212, which are currently in clinical trials. ORNL's initiatives include the Accelerating Radiotherapeutics through Advanced Molecular Constructs (ARM) program, which focuses on creating advanced molecular constructs for labeling radioisotopes while preserving sensitive biological molecules. Another initiative, the Development and Advancement of Radiopharmaceutical Therapies (DART), aims to combine therapies and imaging for diagnosing and treating diseases, supported by a $20 million investment. Research also emphasizes developing new chelators and nanoparticles for improved targeting and delivery of radioisotopes, incorporating artificial intelligence and quantum simulations to enhance understanding of their behaviors in treatments.
Mon, 16 Mar 2026 14:52:00 GMT | Mirage News